These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Rifalazil retains activity against rifampin-resistant mutants of Chlamydia pneumoniae. Rothstein DM; Suchland RJ; Xia M; Murphy CK; Stamm WE J Antibiot (Tokyo); 2008 Aug; 61(8):489-95. PubMed ID: 18997387 [TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind study comparing single-dose rifalazil with single-dose azithromycin for the empirical treatment of nongonococcal urethritis in men. Stamm WE; Batteiger BE; McCormack WM; Totten PA; Sternlicht A; Kivel NM; Sex Transm Dis; 2007 Aug; 34(8):545-52. PubMed ID: 17297383 [TBL] [Abstract][Full Text] [Related]
9. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Scarpignato C; Pelosini I Chemotherapy; 2005; 51 Suppl 1():36-66. PubMed ID: 15855748 [TBL] [Abstract][Full Text] [Related]
10. Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis. Dietze R; Teixeira L; Rocha LM; Palaci M; Johnson JL; Wells C; Rose L; Eisenach K; Ellner JJ Antimicrob Agents Chemother; 2001 Jul; 45(7):1972-6. PubMed ID: 11408210 [TBL] [Abstract][Full Text] [Related]
11. A Comparative Insight on the Newly Emerging Rifamycins: Rifametane, Rifalazil, TNP-2092 and TNP-2198. Nazli A; He DL; Xu H; Wang ZP; He Y Curr Med Chem; 2022; 29(16):2846-2862. PubMed ID: 34365945 [TBL] [Abstract][Full Text] [Related]
13. Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea. Garey KW; Salazar M; Shah D; Rodrigue R; DuPont HL Ann Pharmacother; 2008 Jun; 42(6):827-35. PubMed ID: 18430792 [TBL] [Abstract][Full Text] [Related]
14. Interaction of rifalazil with oxidant-generating systems of human polymorphonuclear neutrophils. Labro MT; Ollivier V; Babin-Chevaye C Antimicrob Agents Chemother; 2005 Dec; 49(12):5018-23. PubMed ID: 16304167 [TBL] [Abstract][Full Text] [Related]
15. Activities of rifamycin derivatives against wild-type and rpoB mutants of Chlamydia trachomatis. Xia M; Suchland RJ; Carswell JA; Van Duzer J; Buxton DK; Brown K; Rothstein DM; Stamm WE Antimicrob Agents Chemother; 2005 Sep; 49(9):3974-6. PubMed ID: 16127086 [TBL] [Abstract][Full Text] [Related]
16. Isolation and identification of major metabolites of rifalazil in mouse and human. Mae T; Konishi E; Hosoe K; Hidaka T Xenobiotica; 1999 Nov; 29(11):1073-87. PubMed ID: 10598743 [TBL] [Abstract][Full Text] [Related]
17. Anti-chlamydial antibiotic therapy for symptom improvement in peripheral artery disease: prospective evaluation of rifalazil effect on vascular symptoms of intermittent claudication and other endpoints in Chlamydia pneumoniae seropositive patients (PROVIDENCE-1). Jaff MR; Dale RA; Creager MA; Lipicky RJ; Constant J; Campbell LA; Hiatt WR Circulation; 2009 Jan; 119(3):452-8. PubMed ID: 19139383 [TBL] [Abstract][Full Text] [Related]
18. In vitro time-kill activities of rifalazil, alone and in combination with vancomycin, against logarithmic and stationary cultures of Staphylococcus aureus. Osburne MS; Rothstein DM; Farquhar R; Murphy CK J Antibiot (Tokyo); 2006 Feb; 59(2):80-5. PubMed ID: 16629407 [TBL] [Abstract][Full Text] [Related]
20. Effect of food on the pharmacokinetics of rifalazil, a novel antibacterial, in healthy male volunteers. Chen YX; Cabana B; Kivel N; Michaelis A J Clin Pharmacol; 2007 Jul; 47(7):841-9. PubMed ID: 17463218 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]